Influenza A/H3N2 challenge model for CHIM studies
Developing influenza vaccines or antivirals requires early confidence before progressing to larger, more complex clinical trials. Traditional field studies depend on seasonal virus circulation and offer limited control over infection timing and clinical outcomes. Controlled human infection model (CHIM) studies address these challenges by enabling infection under carefully controlled conditions, with intensive sampling and standardized evaluation of virological and clinical endpoints.
In this factsheet, we present the clinical validation of our GMP-validated, Influenza A/H3N2 challenge model. The challenge agent has been used across multiple studies in healthy volunteers for over a decade, demonstrating reliable infection rates and reproducible viral kinetics with mild to moderate, self‑resolving respiratory symptoms.
What you’ll find in in this technical sheet:
- Development of the influenza challenge agentLearn how the H3N2 challenge strain was clinically validated, manufactured under cGMP conditions and supported by non-clinical characterization prior to use in human studies.
- Study design and clinical setupExplore the clinical framework, including controlled inoculation, quarantine conditions and high-frequency sampling to monitor viral and clinical responses.
- Results on viral kinetics and symptom profileReview key findings, including rapid viral detection within 24 hours, peak viral load at approximately 60 hours and a consistent, mild-to-moderate symptom pattern resolving before discharge.
- The role of CHIM in early influenza developmentUnderstand how CHIM studies enable early efficacy assessment, dose optimization and more informed go/no-go decisions before advancing to larger trials.